CORDIS
EU research results

CORDIS

English EN
Controlling Cartilage to Bone Transitions for Improved Treatment of Bone Defects and Osteoarthritis

Controlling Cartilage to Bone Transitions for Improved Treatment of Bone Defects and Osteoarthritis

Objective

A well-functioning locomotor system is essential for human well-being. This is an important consideration in our aging population with the increased associated costs of ensuring high quality of life. Many people suffer from diseases of the locomotor system, such as bone defects or osteoarthritis, for which current treatments are insufficient. To develop new treatments, CarBon includes 6 academic partners, 3 companies and 3 charitable foundations, working together to train 14 young scientists. We will combine knowledge from the fields of tissue engineering, cartilage and bone developmental biology and pathobiology using skills from the disciplines of cell biology, computational modelling, biotechnology (bioreactors, biomaterials) and drug discovery.

In a multifactorial approach the network of young scientists will identify the biological and physical factors that determine the fate of cartilage. Understanding and controlling the dual character of cartilage is pivotal: insufficient transition impairs bone healing, and undesired transition to bone leads to osteoarthritis. State of the art in vitro, in silico and in vivo models will be uniquely combined to elucidate how this transition is orchestrated and how it can be modulated.

The main objectives of CarBon are:
- To establish a network of 14 highly skilled early stage researchers (ESRs) equipped with essential knowledge, scientific expertise, transferable skills and societal awareness as a foundation for their future careers. ESRs will be trained in cutting edge technology, communication, intellectual property and valorisation.
- To understand cartilage to bone transition, to identify targets to develop novel functionalised biomaterials and to discover therapeutic drugs that either prevent or stimulate cartilage to bone transitions. This will lead to new treatment options for large bone defects and osteoarthritis.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Address

Dr Molewaterplein 40
3015 Gd Rotterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 766 122,84

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 751 680

IRCCS OSPEDALE POLICLINICO SAN MARTINO

Italy

EU Contribution

€ 258 061,32

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Ireland

EU Contribution

€ 265 674,60

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 249 216,48

THE ROYAL VETERINARY COLLEGE

United Kingdom

EU Contribution

€ 546 575,76

SURGACOLL TECHNOLOGIES LIMITED

Ireland

EU Contribution

€ 265 674,60

LIFETEC GROUP BV

Netherlands

EU Contribution

€ 255 374,28

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 249 216,48

Partners (4)

Sort alphabetically

Expand all

STICHTING NATIONAAL REUMAFONDS

Orthopaedic Research UK

Deutsche Arthrosehilfe

Eli Lilly and Company

Project information

Grant agreement ID: 721432

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 607 596,36

  • EU contribution

    € 3 607 596,36

Coordinated by:

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands